Lyka Labs Limited (LYKALABS.NS)
INR 156.41
(1.68%)
INR 156.41
(1.68%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.05 Billion INR | 19.47% |
| 2022 | 930.72 Million INR | -49.3% |
| 2021 | 1.83 Billion INR | 173.57% |
| 2020 | 671.07 Million INR | 21.12% |
| 2019 | 554.07 Million INR | -13.75% |
| 2018 | 642.37 Million INR | 13.98% |
| 2017 | 563.59 Million INR | -51.66% |
| 2016 | 1.16 Billion INR | -8.61% |
| 2015 | 1.27 Billion INR | -23.28% |
| 2014 | 1.66 Billion INR | 39.89% |
| 2013 | 1.18 Billion INR | -6.5% |
| 2012 | 1.27 Billion INR | 0.0% |
| 2011 | - INR | -100.0% |
| 2010 | 1.39 Billion INR | -14.94% |
| 2009 | 1.63 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 301.14 Million INR | 8.45% |
| 2023 Q2 | 279.86 Million INR | 22.33% |
| 2023 FY | 1.11 Billion INR | 19.47% |
| 2023 Q3 | 325.63 Million INR | 16.36% |
| 2023 Q1 | 228.77 Million INR | 2.87% |
| 2023 Q4 | 277.67 Million INR | -14.73% |
| 2022 Q3 | 178.15 Million INR | -30.21% |
| 2022 Q2 | 255.26 Million INR | -7.15% |
| 2022 Q1 | 274.92 Million INR | 11.37% |
| 2022 FY | 930.72 Million INR | -49.3% |
| 2022 Q4 | 222.38 Million INR | 24.83% |
| 2021 Q3 | 355.73 Million INR | -51.86% |
| 2021 Q2 | 738.89 Million INR | 49.46% |
| 2021 Q1 | 494.36 Million INR | 865.94% |
| 2021 FY | 1.83 Billion INR | 173.57% |
| 2021 Q4 | 246.86 Million INR | -30.61% |
| 2020 Q2 | 174.55 Million INR | -1.49% |
| 2020 FY | 671.07 Million INR | 21.12% |
| 2020 Q3 | 268.14 Million INR | 53.61% |
| 2020 Q4 | 51.18 Million INR | -80.91% |
| 2020 Q1 | 177.19 Million INR | 95.51% |
| 2019 Q4 | 90.62 Million INR | -50.63% |
| 2019 Q1 | 143.64 Million INR | -17.19% |
| 2019 FY | 554.07 Million INR | -13.75% |
| 2019 Q2 | 136.22 Million INR | -5.17% |
| 2019 Q3 | 183.57 Million INR | 34.76% |
| 2018 Q2 | 151.6 Million INR | -78.58% |
| 2018 Q4 | 173.46 Million INR | -3.48% |
| 2018 FY | 642.37 Million INR | 13.98% |
| 2018 Q1 | 707.8 Million INR | 0.0% |
| 2018 Q3 | 179.71 Million INR | 18.55% |
| 2017 FY | 563.59 Million INR | -51.66% |
| 2016 Q1 | 211.79 Million INR | -67.06% |
| 2016 FY | 1.16 Billion INR | -8.61% |
| 2016 Q4 | 306.02 Million INR | -4.07% |
| 2016 Q3 | 319 Million INR | -3.04% |
| 2016 Q2 | 329 Million INR | 55.34% |
| 2015 Q2 | 353.88 Million INR | -25.94% |
| 2015 Q4 | 642.93 Million INR | 109.22% |
| 2015 Q3 | 307.3 Million INR | -13.16% |
| 2015 Q1 | 477.84 Million INR | 11.1% |
| 2015 FY | 1.27 Billion INR | -23.28% |
| 2014 Q2 | 337.67 Million INR | 89.5% |
| 2014 Q1 | 178.19 Million INR | 0.0% |
| 2014 Q4 | 430.09 Million INR | -10.02% |
| 2014 Q3 | 477.98 Million INR | 41.55% |
| 2014 FY | 1.66 Billion INR | 39.89% |
| 2013 Q3 | 176.68 Million INR | -31.31% |
| 2013 FY | 1.18 Billion INR | -6.5% |
| 2013 Q1 | 231.26 Million INR | -38.58% |
| 2013 Q2 | 257.2 Million INR | 11.22% |
| 2012 Q2 | 340.8 Million INR | 13.12% |
| 2012 Q4 | 376.5 Million INR | 41.78% |
| 2012 Q3 | 265.55 Million INR | -22.08% |
| 2012 FY | 1.27 Billion INR | 0.0% |
| 2012 Q1 | 301.27 Million INR | 0.0% |
| 2011 FY | - INR | -100.0% |
| 2011 Q3 | 201.81 Million INR | 0.0% |
| 2010 FY | 1.39 Billion INR | -14.94% |
| 2009 FY | 1.63 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Biocon Limited | 147.55 Billion INR | 99.288% |
| Blue Jet Healthcare Limited | 7.11 Billion INR | 85.226% |
| Concord Biotech Limited | 9.98 Billion INR | 89.466% |
| Dishman Carbogen Amcis Limited | 26.15 Billion INR | 95.981% |
| Jubilant Ingrevia Limited | 41 Billion INR | 97.436% |
| Panacea Biotec Limited | 5.59 Billion INR | 81.199% |
| Piramal Pharma Limited | 81.71 Billion INR | 98.713% |
| SMS Lifesciences India Limited | 3.05 Billion INR | 65.638% |
| Supriya Lifescience Limited | 5.7 Billion INR | 81.568% |
| Syngene International Limited | 34.88 Billion INR | 96.986% |
| TAKE Solutions Limited | 656.08 Million INR | -60.243% |
| Zota Health Care Limited | 1.8 Billion INR | 41.751% |